Beam Therapeutics Inc. (BEAM) vs Immunome, Inc. (IMNM)
Beam Therapeutics Inc. and Immunome, Inc. are both Biotechnology companies. Beam Therapeutics Inc. and Immunome, Inc. are of similar size ($2.6B and $2.6B). Beam Therapeutics Inc. grew revenue faster over the last twelve months: 158.9% against 16.7%. Immunome, Inc. has the higher net margin (0.00% vs −55.5%) and the lower return on invested capital (−3,323.0% vs −1,599.3%). Across the 16 metrics below, Beam Therapeutics Inc. leads on 9 and Immunome, Inc. on 7.
Valuation
Profitability
| Metric | BEAM | IMNM | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (242.27%) | 0.00% | 0.00% |
| Net margin | (55.45%) | 0.00% | 0.00% |
| Free cash flow margin | (238.90%) | 0.00% | 0.00% |
| Return on equity | (8.18%) | (64.03%) | (57.72%) |
| Return on assets | (6.23%) | (59.03%) | (49.22%) |
| Return on invested capital | (1,599.30%) | (3,322.99%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack